Basal cell carcinoma - Pipeline Insight, 2021

DelveInsights, Basal cell carcinoma - Pipeline Insight, 2021, report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Basal cell carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Basal cell carcinoma Understanding
Basal cell carcinoma: Overview
Basal cell carcinoma (BCC) is a common, locally invasive, keratinocyte cancer (also known as nonmelanoma cancer). It is the most common form of skin cancer. BCC is also known as rodent ulcer and basalioma. The main characteristics are: Slowly growing plaque or nodule, Skin colored, pink or pigmented, Varies in size from a few millimeters to several centimeters in diameter, Spontaneous bleeding or ulceration. Ultraviolet (UV) rays from the sun or from a tanning bed are the main cause of basal cell carcinoma. The goal of treatment for basal cell carcinoma is to remove the cancer completely. The clinical appearance, size, site, and histologic subtype determine choice of treatment: curettage and electrodesiccation, surgical excision, cryosurgery, topical chemotherapy (imiquimod or 5-fluorouracil) and photodynamic therapy, or, occasionally, radiation therapy. Large or recurrent basal cell cancers are treated best with Mohs surgery (a specialized type of microscopically controlled surgery).

"Basal cell carcinoma - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Basal cell carcinoma pipeline landscape is provided which includes the disease overview and Basal cell carcinoma treatment guidelines. The assessment part of the report embraces, in depth Basal cell carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Basal cell carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Basal cell carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Basal cell carcinoma.

Basal cell carcinoma Emerging Drugs Chapters
This segment of the Basal cell carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Basal cell carcinoma Emerging Drugs
Patidegib: PellePharm
Patidegib is an investigational small molecule that inhibits hedgehog signaling. It is a topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. Topical patidegib is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor exclusively licensed from Infinity Pharmaceuticals. Patidegib is currently evaluated in Phase III clinical trials for the treatment of BCCs.

AIV001: AiViva BioPharma
AIV001 is a novel formulation of a multi-kinase inhibitor combined with AiVivas proprietary delivery technology, designed for prolonged drug release via intradermal treatment. AIV001 targets multiple pathways to reduce fibroplasia in overlapping phases of wound healing and scarring; targets VEGFR to limit the inflammation and fibrosis associated with rosacea; and inhibits or reduces neovascularization and cell proliferation associated with certain cancers. AIV001 is in Phase I/II clinical studies for the treatment of patients with Basal Cell Carcinoma.
Further product details are provided in the report..

Basal cell carcinoma: Therapeutic Assessment
This segment of the report provides insights about the different Basal cell carcinoma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Basal cell carcinoma
There are approx. 25+ key companies which are developing the therapies for Basal cell carcinoma. The companies which have their Basal cell carcinoma drug candidates in the most advanced stage, i.e. Phase III include, PellePharm.

Phases
DelveInsights report covers around 25+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration
Basal cell carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
Intravitreal
Subretinal
Topical

Molecule Type
Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Basal cell carcinoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Basal cell carcinoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Basal cell carcinoma drugs.

Basal cell carcinoma Report Insights
Basal cell carcinoma Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Basal cell carcinoma Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Basal cell carcinoma drugs?
How many Basal cell carcinoma drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Basal cell carcinoma?
What are the key collaborations (IndustryIndustry, IndustryAcademia), Mergers and acquisitions, licensing activities related to the Basal cell carcinoma therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Basal cell carcinoma and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
PellePharm
MedC Biopharma Corporation
AiViva BioPharma
MediWound
Kintara Therapeutics
IO Biotech
Sirnaomics
Aresus Pharma
Epitome Pharmaceuticals
Transgene
Senhwa Biosciences
Palvella Therapeutics
Suzhou Kintor Pharmaceuticals
Leaf Vertical

Key Products
AIV001
Patidegib
MDC-2060
MWPC 005
Rostaporfin
IO103
STP 705
Polyphenon E
AIV 001
TG 1042
Silmitasertib
Sirolimus topical
GT 1708F
Cannabidiol

Introduction
Executive Summary
Basal cell carcinoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Basal cell carcinoma DelveInsights Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Patidegib: PellePharm
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
IO103: IO Biotech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I/II)
Comparative Analysis
AIV001: AiViva BioPharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
Cannabidiol: Leaf Vertical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Basal cell carcinoma Key Companies
Basal cell carcinoma Key Products
Basal cell carcinoma- Unmet Needs
Basal cell carcinoma- Market Drivers and Barriers
Basal cell carcinoma- Future Perspectives and Conclusion
Basal cell carcinoma Analyst Views
Appendix

List Of Tables

Table 1 Total Products for Basal cell carcinoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

Figure 1 Total Products for Basal cell carcinoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available